Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was
initially developed more than a decade ago to overcome toxicities associated with the …

Non-small-cell lung cancer (NSCLC) is a very common disease in the elderly population
and its incidence in this particular population is expected to increase further, because of the …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

Lung cancer is one of the leading causes of cancer-related death worldwide. Non-small cell
lung cancer (NSCLC) causes around 80% to 90% of deaths. The lack of an early diagnosis …

Introduction: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor,
has demonstrated clinical efficacy in the treatment of advanced non-small cell lung cancer …

Although recent advances in molecular targeted therapy and immuno-oncology have
revolutionized the landscape of lung cancer therapeutics, cytotoxic chemotherapy remains …

Improving the efficacy-toxicity balance of anticancer agents remains an ongoing challenge
in oncology. Beside the ever-growing development of innovative drugs addressing newly …

Lung cancer is the leading cause of cancer mortality worldwide in both men and women.
Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for …

Lung cancer is by far the leading cause of cancer-related mortality worldwide, most of them
being active tobacco smokers. Non small cell lung cancer accounts for around 85% to 90 …